- Home
- GALT
as 11-24-2025 3:41pm EST
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | NORCROSS |
| Market Cap: | 232.3M | IPO Year: | N/A |
| Target Price: | $6.00 | AVG Volume (30 days): | 443.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.59 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.73 - $6.55 | Next Earning Date: | 11-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Galectin Therapeutics Inc. (GALT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| LEWIS JOEL | GALT | President and CEO | Nov 18 '25 | Sell | $6.15 | 6,783 | $41,722.91 | 832,592 | |
| CALLICUTT JACK W | GALT | Chief Financial Officer | Nov 18 '25 | Sell | $6.22 | 46,310 | $288,187.13 | 7,614 | |
| LEWIS JOEL | GALT | President and CEO | Nov 17 '25 | Sell | $6.04 | 15,680 | $94,642.91 | 832,592 | |
| CALLICUTT JACK W | GALT | Chief Financial Officer | Nov 17 '25 | Sell | $6.03 | 31,610 | $190,662.04 | 7,614 | |
| Jamil Khurram | GALT | Chief Medical Officer | Nov 13 '25 | Sell | $5.47 | 121,117 | $662,509.99 | 4,479 | |
| 10X Fund, L.P. | GALT | 10% Owner | Nov 11 '25 | Sell | $5.25 | 40,000 | $210,000.00 | 5,832,207 | |
| LEWIS JOEL | GALT | President and CEO | Nov 10 '25 | Sell | $6.03 | 1,867 | $11,252.22 | 832,592 | |
| CALLICUTT JACK W | GALT | Chief Financial Officer | Nov 10 '25 | Sell | $6.03 | 5,291 | $31,883.65 | 7,614 | |
| LEWIS JOEL | GALT | President and CEO | Nov 5 '25 | Sell | $6.00 | 200 | $1,200.00 | 832,592 | |
| CALLICUTT JACK W | GALT | Chief Financial Officer | Nov 5 '25 | Sell | $6.00 | 600 | $3,600.00 | 7,614 |
Latest Galectin Therapeutics Inc. News
GALT Breaking Stock News: Dive into GALT Ticker-Specific Updates for Smart Investing
MT Newswires
5 days ago
Galectin Therapeutics Insider Sold Shares Worth $478,849, According to a Recent SEC Filing
GlobeNewswire
11 days ago
Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update
GlobeNewswire
15 days ago
Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting
Offshore Technology
21 days ago
Serica Energy to buy 40% interest in North Sea licence
PR Newswire
21 days ago
Aptiv Receives Frost & Sullivan's 2025 Global Product Leadership Recognition for Excellence in Automotive Assisted Parking Solutions
PR Newswire
21 days ago
Republic Business Credit Supports Growth of Innovative Ice Cream Manufacturer with $1 Million Factoring Facility
PR Newswire
21 days ago
Movate and Lyzr.ai Announce Strategic Partnership to Accelerate Enterprise AI Transformation
PR Newswire
21 days ago
Kinterra Capital Secures US $200 Million in Indicative EXIM Support to Fully Fund Pumpkin Hollow Restart and Advance Southwest Open Pit
Compare GALT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GALT Galectin Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.